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ABSTRACT
OPIOID ADDICTION AND PREGNANCY: POTENTIAL EFFECTS OF
SUBSTITUTION THERAPIES ON DEVELOPMENTAL MYELINATION
By Andrew Cappel Eschenroeder

A dissertation submitted in partial fulfillment of the requirements for the degree of
Master of Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2010

Thesis Director: Carmen Sato-Bigbee, Ph.D.
Associate Professor, Department of Biochemistry and Molecular Biology

While most cells of the central nervous system (CNS) express opioid
receptors, the role of the endogenous opioid system in CNS development
remains poorly understood.
Identification of opioid functions during brain maturation is particularly
crucial in light of the increasing trend in opioid abuse and the use of opioid drugs
during pregnancy. New substitution therapies in pregnant opioid addicts include
buprenorphine, a mu opioid receptor partial agonist and kappa opioid receptor
antagonist. However, while clinical studies demonstrated buprenorphine efficacy

	
  

	
   x	
  
in reducing neonatal withdrawal symptoms, there is a lack of information on the
potential effects of this drug on brain development.
Previous work from our laboratory has shown that perinatal exposure to
buprenorphine induces dose-dependent alterations in rat brain myelination.
These time-specific effects suggested that both therapeutic and supratherapeutic doses of the drug could alter the normal pattern of oligodendrocyte
development. In support of this hypothesis, this thesis work has now found that
buprenorphine exerts direct actions on the oligodendrocytes that are highly
dependent on both the drug dose and stage of cell differentiation. When
exposed to buprenorphine, oligodendrocyte progenitors isolated from 3-day-old
rat brain exhibit increased cell proliferation. In contrast, treatment of more mature
oligodendrocytes obtained from 9-day-old rat brain induces dramatic dosespecific effects on cell process network extension and membrane outgrowth.
These later effects are accompanied by significant parallel changes in the
expression of the four major splicing isoforms of myelin basic protein (MBP), a
critical component of the myelin membrane and mature myelinating
oligodendrocytes. Furthermore, similar dose-specific effects on MBP expression
are also elicited by methadone, a mu opioid receptor agonist already approved
for the treatment of pregnant opioid addicts. Experiments with CTOP, a highly
selective antagonist of the mu opioid receptor, further contribute to the idea that
this receptor subtype plays an important function in controlling oligodendrocyte
maturation.
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These findings underscore the potential effects of opioid exposure during
brain maturation and further indicate an important regulatory role of the
endogenous opioid system in the control of oligodendrocyte development and
myelination.

	
  

	
  

INTRODUCTION
Epidemiological data show an increasing incidence of opioid abuse
(Compton and Volkow, 2006), a critical problem among pregnant addicts.
Surprisingly, little is known about the effects of these drugs on child
development, although several clinical studies suggest that their use during
pregnancy may interfere with the formation of the central nervous system (CNS).
Infants exposed to opioids in utero exhibit reduced head circumference,
decreased attention, altered fine motor coordination, and a greater risk of sudden
infant death syndrome (Rosen and Johnson, 1982, Marcus et al., 1984, Kandall
et al., 1993). In addition, longitudinal studies found that these children showed
heightened activity, impulsivity, and reduced attention span, suggesting
underlying neurological problems (Hutchings, 1982). However, the effects of
perinatal exposure to opioids on brain development are difficult to assess
because behavioral and cognitive outcomes in children are known to be highly
influenced by environmental, educational, and lifestyle factors (Ornoy et al.,
2001).
The current FDA approved standard treatment for opioid addiction during
pregnancy is substitution therapy with methadone, even though this mu opioid
receptor agonist has been linked to neonatal abstinence syndrome upon
discontinuation (Fischer et al., 2006, Lejeune et al., 2006). One alternative
possibility is the use of buprenorphine. This mu partial agonist and kappa
antagonist has been approved to treat opioid-dependent adults in the United
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States and is also being used experimentally in pregnant addicts in this and
several other countries. Clinical trials indicate that buprenorphine is effective in
the prevention of “street opioid” abuse by pregnant addicts as well as reducing
the incidence and severity of neonatal abstinence syndrome (Jones et al., 2005,
Ebner and Wiedmann, 2006). However, as indicated above, not much is known
about the potential effects of these treatments on the developing CNS.
The brain is most vulnerable to insults during development when critical
periods of network establishment and refinement are underway. Recent studies
suggest that a major factor in the coordination of these events is the endogenous
opioid system. Both neurons and glia express opioid receptors and endogenous
opioid peptides in a developmentally controlled manner (Wu et al., 1997, Ikeda et
al., 1998, Knapp et al., 1998, Leslie et al., 1998, Miller and Azmitia, 1999, Kivell
et al., 2004). In this regard, perinatal exposure of rats to buprenorphine has been
shown to delay the generation of cholinergic neurons (Robinson, 2002) and to
reduce the expression of nerve growth factor in the striatum (Wu et al., 2001),
underscoring the importance of further research on the actions of this drug in
CNS development.
Interestingly, previous work from our laboratory has shown that
buprenorphine affects the formation of myelin (Sanchez et al., 2008), the
multilamellar membrane that insulates axons allowing the rapid saltatory
conduction of nerve impulses. In the CNS, the myelin membrane is produced by
oligodendrocytes, a type of glial cell, which is the center of these studies and will
be described in detail in the following sections of this thesis. The synthesis of
2	
  

	
  
myelin is under control of multiple growth factors and hormonal signals as well as
cell-cell interactions, making this a particularly vulnerable process during CNS
development. The observed effects of buprenorphine on myelination beg further
investigation, as the roles of opioid receptors in oligodendrocyte development
and in vivo myelination are unknown.
This work investigates the direct effects of opioids on developing
oligodendrocytes in vitro. Characterizing these specific effects will help to further
understand the in vivo role of the endogenous opioid system in controlling
myelination as well as provide important clues for the development of therapeutic
interventions for pregnant opioid addicts.
First, a background of opioids and glia will be given before we investigate
their coordinated effects on oligodendrocyte development and function.

OPIOIDS
Opioids comprise a family of drugs that has long been used to relieve
various types of pain. Opiates were originally defined as derivatives of the opium
poppy (papaver somniferum). However, the modern term “opioids”
encompasses opiates as well as synthetic and endogenous molecules, all of
which are able to interact with opioid receptors. Today, these compounds are
widely used for their analgesic properties as well as their inhibitory effects on the
digestive system.
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Opioids have been used medicinally for thousands of years. The use of
opium for pain management and dysentery treatment existed in antiquity, but did
not become widespread until the mid-19th century. The global opium trade
originated in the Middle East and was facilitated by the imperial campaigns of the
British Empire. Soon, opium use spread to the Far East as well as Western
Europe. Opioids had previously been available in the United States, but at the
turn of the century their use expanded dramatically. Heroin was widely used to
relieve cough, as well as a range of maladies from digestive problems to
menstrual pain. However, these substances are characterized by their high
potential for abuse, resulting in serious clinical manifestations and making users
vulnerable to severe withdrawal upon cessation. As they became readily
available, the incidence of opiate abuse rose. By 1914, the US government
acknowledged the growing problem and brought opioids under federal regulation
by passing the Harrison Act (Acker, 2002). Presently, opioids are clinically
available by prescription only. Yet opioid abuse remains a problem worldwide.

Physiological Effects of Opioids
Opioids are the most effective drugs known for pain relief. At therapeutic
doses, they successfully suppress pain with a minimal effect on other sensations.
Opioid analgesia is specific to ‘second pain’: the dull ache after noxious stimulus,
or ‘first pain’ (Cooper et al., 1986). This may explain the evolutionary significance
of the endogenous opioid system—dulling second pain does not hinder
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perception of future noxious stimuli. Opioids have also been shown to reduce
emotional pain, which is a major factor in their high potential for addiction.
These drugs cause marked physiological changes when consumed at
analgesic doses. Decreased body temperature and pituitary function, respiratory
depression, pupil constriction, suppressed cough reflex, nausea, decreased
gastrointestinal secretions and motility, and suppression of the immune system
are all observed. In neurons, opioids presynaptically inhibit the release of small
nociceptors via the inhibition of calcium channels (Taddese et al., 1995).

Opioid Subtypes
Naturally Occurring Opiates
The naturally occurring opiates are alkaloids derived from the papaver
somniferum plant. Morphine is the predominant type, but codeine and thebaine
can also be derived from the plant (Martin, 1967).
Synthetic Opioids
Synthetic opioids are the largest subtype and constitute the majority of
molecules within this group that are used for pharmaceutical purposes (Portenoy,
1993). These substances have molecular structures analogous to those of
naturally occurring opioid alkaloids. Examples include diacetylmorphine (heroin),
hydrocodeine, oxycodone, fentanyl, methadone, and buprenorphine. Along with
morphine, many synthetic derivatives are used clinically for pain management.
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Buprenorphine and methadone, notably, are used to treat opioid addiction by
mitigating withdrawal symptoms through replacement therapy (Figure 1). These
two drugs will be described in more detail in following sections of this thesis as
their administration to pregnant opioid addicts has the potential of affecting
crucial steps along brain development.
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Figure 1. The molecular structures of buprenorphine and methadone. These
synthetic opioids are commonly used in replacement therapy.
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Endogenous Opioids
Interestingly, the human body produces endogenous opioid peptides that
were discovered as a result of initial studies investigating exogenous opioid
actions and the role of different opioid receptors. Many of the original studies
used high-affinity alkaloids to identify opioid receptor types. Morphine was used
to identify the mu receptor, ketocyclazocine for the kappa receptor (Lord et al.,
1977). However, a stimulation-induced analgesia was observed in animals that
could be reversed with the administration of naloxone, a known opioid receptor
antagonist (Mayer et al., 1971). The first two peptide candidates for mediating
this response were methionine- and leucine-enkephalin, endogenous peptides
consisting of five amino acid residues (Waterfield et al., 1976). Shortly thereafter,
β-endorphin and dynorphin were isolated. The enkephalins, endorphins, and
dynorphins make up the three distinct groups of endogenous opioid peptides.
The constituents of these three groups differentially bind the mu, delta, and
kappa opioid receptors with varying affinity. The ORL-1 receptor only binds the
endogenous peptides nociceptin and orphanin FQ (Meunier et al., 1995,
Reinscheid et al., 1995).

Opioid Receptors
All opioids bind to at least one type of opioid receptor. This family of
receptors is comprised of the mu opioid receptor, the kappa opioid receptor, the
delta opioid receptor, and the opioid receptor-like 1 receptor (ORL-1). This
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nomenclature was derived from radiolabeled ligand affinity studies. For example:
the mu receptor was defined and characterized by its high affinity for morphine.
These studies revealed stereospecific, saturatable binding kinetics (Pert et al.,
1973), along with the differential distribution of mu, delta, and kappa in the brain
with a high concentration present in areas relevant to pain, including the
periaqueductal grey, medial thalamus, and amygdala (Hiller et al., 1973, Kuhar et
al., 1973, Pert et al., 1976). ORL-1 was discovered decades later through
sequence homology studies. Like the other receptors, it was cloned and shown
to match the endogenous receptor. Originally, it was named the N/OFQ receptor
for its endogenous ligands: nociceptin and oprhanin FQ (Butour et al., 1997). It
differs from mu, delta, and kappa receptors by its negligible response to
naloxone—a potent antagonist to the three other receptors. In addition, ORL-1
does not bind any of the other endogenous opioid peptides.
The mu, delta, and kappa opioid receptors exhibit both high structural and
functional homology. These molecules are G-protein coupled receptors (GPCR)
with seven transmembrane domains spanning the phospholipid bilayer. The
receptor is coupled to a heterotrimeric G-protein that acts as the transducer
between receptor and the eventual effector response. These G-proteins are
composed of three subunits whose activity is regulated by allosteric interaction
with guanosine triphosphate (GTP) and guanosine diphosphate (GDP). When
bound by an agonist, opioid receptors inhibit adenylyl cyclase activity through
activation of the Gi/G0 G-protein. These G-proteins can also affect phospholipase
C, mitogen-activated protein kinase (MAPK), and ion channel activity. Gi/G0
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appears to be the G-protein most prominently involved in these primary
transduction mechanisms, but opioid receptors have also been linked to other Gproteins that mediate secondary transduction mechanisms (e.g. Gq, G11, G12,
G13, and G16) (Lee et al., 1998, Ho et al., 2002). These primary and secondary
effects alter levels of second messengers like cyclic adenosine monophosphate
(cAMP), diacylglycerol (DAG), and inositol triphosphate (IP3), signaling molecules
which can regulate the expression and activation of various kinases and
transcription factors and eventually cause changes in gene regulation. The mu,
delta, and kappa receptors all have constitutive levels of activity, so responses to
ligand binding are modulatory as opposed to binary.
GPCRs are subject to desensitization and endocytosis with chronic opioid
use. β-arrestin is recruited to the receptor after it is phosphorylated by G protein
receptor kinase and decouples the receptor from the G protein. Unlike other
models of chronic receptor activation, opioid receptor levels do not decrease
dramatically over time. One hypothesis is that the GPCR becomes dissociated
from its downstream effectors and therefore is less effective in inhibiting adenylyl
cyclase (Christie et al., 1987).

GLIAL CELLS
The neuronal doctrine has dictated the study of brain function and brought
about our current understanding of the nervous system. This dogma proffers that
neurons and the synapses adjoining their networks are the primary units of the
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nervous system structure and function. In recent years, however, this view has
been borne out as incomplete. Glial cells were characterized by Virchow as
“nervenkitt” (nerve glue) upon their discovery, but they are increasingly
implicated in signaling, development, plasticity, and other functional aspects of
the brain. Recent evidence suggests that glial networks act in concert with
neurons to refine and control the nervous system.

Glia Characteristics
Glia consist of five cell types: astroglia, microglia, oligodendrocytes,
ependymal cells of the CNS, and the Schwann cells of the peripheral nervous
system (PNS). Each of these cell groups possesses an array of functions which
are integral to nervous system physiology. Along with neurons, glial types
constitute the main categories of cells in the CNS. Neurons differ from glia in
their ability to conduct action potentials. However, the inability of glia to
propagate these all-or-none electrical signals does not designate them as static
entities; rather, they refine circuits by limiting and directing electrical propagation.
Surprisingly, glia are the predominant cell type while neurons account for
only 20%-40% of all cells in the CNS. The macroglia, of ectodermal origin, are
comprised of astrocytes (60-80%), ependymal cells (5%), and oligodendrocytes
(5%-10%). Microglia originate from the mesoderm and under normal noninflammatory conditions they make up 10% of the CNS glia.
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Glial morphology and distribution was thoroughly described in the 19th
century by histologists Camillo Golgi, Santiago Ramón y Cajal, and Pio Del Rio
Hortega. Yet, investigation of their functional importance was not conducted until
recent decades. Glial coupling and networks were first observed in the 1960’s
(Kuffler and Nicholls, 1966, Brightman and Reese, 1969). However, technological
improvements were necessary for advancing the study of glial function, and, in
1984, receptors for the neurotransmitters glutamate and gamma-aminobutyric
acid (GABA) were discovered in astrocytes and oligodendrocytes (Bowman and
Kimelberg, 1984, Kettenmann et al., 1984a, Kettenmann et al., 1984b). In recent
years, glia have shed their label as the mortar of the CNS and proven to play a
variety of functional roles. Astrocytes are known to express multiple receptors
and enzymatic systems whose main functions are to maintain nervous system
homeostasis and to limit neurotransmitter availability. These cells are also
implicated in the induction and formation of the blood brain barrier and
developmental synaptogenesis (Barker and Ullian, 2010, Giaume et al., 2010,
Christopherson et al., 2005).
On the other hand, oligodendrocytes are responsible for making the
myelin membrane in the CNS. Schwann cells represent their counterparts in the
PNS. Oligodendrocytes are the center of these studies and therefore, they will be
described in greater detail in the following sections.
Importantly, The ability of both astrocytes and oligodendrocytes to
respond to neurotransmitters (Karadottir et al., 2005); together with the newly
established presence of glial networks (Verkhratsky et al., 2009), has profoundly
13	
  

	
  
implicated glia in current neurobiological studies, challenging many preconceived
ideas on the organization and functioning of the CNS.

The Myelin Membrane
Myelin Structure
Myelin is a specialized multilamellar structure that ensheaths axons in the
vertebrate nervous system. It is a three-dimensional structure formed by the
extension and concentric wrapping of the oligodendroglial membrane, remaining
continuous with the oligodendrocyte. A single oligodendrocyte can myelinate 1030 axons simultaneously and multiple oligodendrocytes are responsible for
generating the different myelin internodes along a single axon, resulting in a
highly intricate glial-neuronal network (Baumann and Pham-Dinh, 2001).
A periodicity to myelin exists; it is generated along the axons as 150-200
nanometer-long longitudinal segments called internodes (Butt and Ransom,
1989). These internodes are flanked by the nodes of Ranvier: axonal areas
lacking myelin but with an increased density of ion channels. As discussed later,
this periodic distribution of ion channels is determined by the presence of
internodes, and together with the insulating properties of myelin, is the basis for
the rapid saltatory conduction of electrical signals—the impulse jumps from node
to node.
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Cross sections of myelinated axons visualized by electron microscopy
(Figure 2) show that myelin appears as a sequence of dark and less dark lines
separated by lighter zones. The dark line—known as the major period line—is
formed by the fusion of inner cytosolic surfaces of the oligodendrocyte
membrane. On the other hand, the lighter line is the intraperiod or minor dense
line, formed by the compaction of the membrane’s outer leaflets. Uncompacted
areas in the myelin internode are believed to be essential for cellular transport
and myelin maintenance. Because myelin is a dynamic structure its components
must constantly be replaced to account for normal membrane turnover. These
areas of cytoplasm are known as paranodal loops and contain mitochondria, free
polysomes, and smooth endoplasmic reticulum for protein and lipid synthesis.
Paranodal loops tend to be located near nodal regions and form transverse
bands with the periaxonal membrane, which strengthen the connection between
the axon and paranode (Ichimura and Ellisman, 1991). This is markedly different
from myelin in the internodal region, which is separated from the periaxonal
space by an extracellular gap.

The Role of Myelin in Nerve Transmission and Axonal Integrity
In unmyelinated nerve fibers, conduction velocity is mainly dependent on
axonal caliber. In contrast, myelinated fibers allow for rapid conduction velocity
and transmission fidelity without a corresponding increase in axonal caliber. This
is achieved by a fundamental difference in conduction mechanism between both
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types of fibers. In unmyelinated fibers, a uniform distribution of ion channels
throughout the axolemma results in local circuits propagating depolarization in a
continuous manner along the axon. By contrast, myelinated axons only expose
the axonal membrane to the extracellular space at nodal regions. Depolarization
cannot move continuously along the axon due to the high membrane resistance
and absence of ion channels in myelinated internodes. Therefore, depolarization
can only occur at nodes where ion channels are exposed. The impulse jumps
from node to node. This is known as ‘saltatory’ conduction (Figure 3).
Furthermore, several lines of evidence indicate that myelin is also a key
factor in axonal development. It has been shown that myelination can regulate
axonal caliber in the optic nerve as well as neurofilament spacing and
phosphorylation, both of which control axonal radial growth (Hsieh et al., 1994,
Sanchez et al., 1996). Moreover, several lines of evidence have shown that
myelination also exerts control over the distribution of the voltage-gated ion
channels responsible for impulse conduction. Different studies have shown that
the myelin membrane functions as a barrier that limits the lateral movement of
ion channels in the axolemma, restricting the localization of voltage-gated sodium
channels to the nodes of Ranvier while fast voltage-gated potassium channels
are concentrated in the juxtaparanode (Rasband and Trimmer, 2001, Poliak and
Peles, 2003, Rosenbluth, 2009).
In mature vertebrates, myelin also functions as an inhibitor of neurite
outgrowth (Domeniconi et al., 2002). By dampening plasticity, myelin may act to
refine late-developing tracts and preserve established myelinated regions.
16	
  

	
  
Moreover, evidence from demyelinating diseases like multiple sclerosis suggest
that both oligodendrocyte and myelin play an important role in axonal protection
and survival (Nave and Trapp, 2008).
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Figure 2. The myelin sheath forms axonal domains which are essential for
impulse conduction. (A) An electron micrograph from a longitudinal section
from rat spinal dorsal root nerve showing the node of Ranvier flanked by
internodal segments insulated by layers of compact myelin. Each layer of myelin
terminates in a series of loops adjacent to the node of Ranvier (the paranodal
loops) (B) Three axonal domains are defined by axon interactions with
myelinating glia: the Na+ channel-enriched node of Ranvier, the adjacent
paranode where the loops of myelin adhere to the axon through cell-adhesion
molecules linked to the axonal cytoskeleton, the juxtaparanode which contains K+
channels and the internode sealed by compacted layers of myelin membrane to
restrict transmembrane ion currents to the nodal region. Modified from Fields,
RD, Trends Neuroscience, 2008
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Figure 3. Comparison between conduction in a myelinated axon versus an
unmyelinated axon. Arrows show the flow of action potential in local circuits into
the active region of the membrane. (A) In unmyelinated fibers, the current flows
throughout the length of the axon in contrast to (B) myelinated fibers where the
current jumps between adjacent nodes resulting in saltatory conduction. Modified
from Basic Neurochemistry, edited by Siegel, Albers, Brady and Price, Elsevier,
2006.
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Myelin Composition
Myelin is composed of approximately 70% lipid and about 30 % protein,
resulting in a highly hydrophobic membrane. This elevated degree of
hydrophobicity and the compact multilamellar structure of myelin are responsible
for its high insulating capacity.
Although no single lipid is unique to myelin or oligodendrocytes, the
proportions of the various lipids are exclusive characteristics. When compared
with other membranes and cells, both myelin and oligodendrocytes are highly
enriched with glycosphingolipids (e.g. galactosylceramides) and their sulfated
derivates: sulfatides (e.g. sulfogalactosylceramides) which, combined, make up
20 percent of the lipids in myelin (Morell et al., 1973).
In contrast to the lipids, there are characteristic proteins unique to myelin
and oligodendrocytes. Myelin basic protein (MBP) and proteolipid protein (PLP)
represent about 80 percent of the total proteins present in myelin (Morell et al.,
1973).
MBP exists in 3-4 major isoforms, depending on species, ranging in
molecular weight from 14 to 21.5 kDa. Altogether, MBPs constitute about 30
percent of the myelin proteins (Boggs, 2006). The various MBPs are generated
by alternative splicing of a single gene, allowing for precise biological control of
protein isoform expression along development (de Ferra et al., 1985,
Campagnoni, 1988). As further discussed in following chapters of this thesis, the
differential localization of MBP isoforms in oligodendrocytes and myelin suggest
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that some of these proteins may play a role in cell differentiation while others are
mainly structural components of the myelin membrane (Pedraza et al., 1997). In
this regard, studies in MBP-deficient mice have evidenced that MBP is an
essential factor in myelin compaction (Readhead et al., 1987).
The other major myelin protein, PLP, exists in two isoforms (25 & 20 kDa),
also originating from alternative splicing of a single gene (Nave et al., 1987). PLP
may be acylated on cysteine residues, making it a hydrophobic proteolipid
complex. Other myelin and oligodendroglial proteins include the enzyme 2',3'cyclic nucleotide 3'-phosphodiesterase (CNPase) (Wolfgram, 1966), myelinassociated glycoprotein (MAG), and myelin oligodendrocyte glycoprotein (MOG).
Antibodies raised against all of these proteins are frequently used as tools to
study myelin formation and oligodendrocyte development.
Myelination: A Complex Developmental Process
The process of myelination in the developing brain is observed as a wellregulated event, conserved temporally and anatomically, yet the precise signals
and regulatory mechanisms are still poorly understood. Oligodendrocyte
migration and membrane synthesis must be tightly controlled to achieve proper
myelination in the CNS. Given that oligodendrocytes only myelinate axons, it is
evident that specific mechanisms of communication between neurons and
oligodendrocytes must exist. It has been observed that electrical activity along
the axon is essential for proper myelination, but specific molecular interactions
between the axon and oligodendrocyte remain unclear (Tauber et al., 1980). The
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expression of NMDA receptors in oligodendrocytes suggests that Ca2+ signaling
in these glial cells is activated by axonal signals. Further support for signaling
from neurons to myelinating glia is supported by previous findings from this
laboratory indicating that oligodendrocytes respond to different neurotransmitters
activating CREB (Sato-Bigbee et al., 1999), a transcription factor that controls
proliferation, survival, and myelin protein expression in these cells (Afshari et al.,
2001, Saini et al., 2004, Saini et al., 2005). In addition, the spatial coordination
between neurons and myelinating oligodendrocytes may be subjected to control
by astrocytes (Meyer-Franke et al., 1999).
Oligodendrocyte Development
As described previously, the formation of myelin during CNS development
requires the integration of multiple signals and cells. In order to decipher the
complex concert of events that result in proper myelination, it is critical to
understand the development of oligodendrocytes. Mitotically active cells in the
brain that are immunopositive for a chondroitin sulfate proteoglycan—NG2—are
the progenitor cell population which gives rise to oligodendrocytes (Nishiyama et
al., 1996). Different studies have indicated that the NG2+ population may be
multipotent with the ability to generate neurons and astrocytes, but 90 percent of
its progeny is oligodendrocytes.
An oligodendrocyte progenitor cell will arise from an NG2+ cell in
ventricular zones of the brain and spinal cord (Luskin et al., 1988, Price and
Thurlow, 1988). These oligodendrocyte progenitors are migratory and mitotically
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active. They are characterized by the expression of certain transcription factors,
including Olig1, Olig2, SOX10, and Nkx2.2 (Baumann and Pham-Dinh, 2001).
Morphologically, oligodendrocyte progenitors appear as cells with a simple soma
with one or two emerging polar processes.
Once the oligodendrocyte progenitor has migrated to the proper site, local
growth factors drive its continuing maturation. Thyroid hormone (T3) is a terminal
differentiation signal to the oligodendrocyte progenitor, halting its mitotic activity
and effectively inducing its conversion to a pre-oligodendrocyte (Almazan et al.,
1985, Barres et al., 1994). These pre-oligodendrocytes can be identified by their
expression of sulfatides, recognized by the O4 antibody (Bansal et al., 1989).
The onset of CNPase expression is another hallmark of a developing
oligodendrocyte. As they mature, pre-oligodendrocytes begin to form more
complex networks of cells processes. Finally, the expression of MBP, PLP, MAG,
and other characteristic myelin proteins will be observed when the cells develop
into fully differentiated oligodendrocytes (Figure 4). This developmental
sequence can be replicated in vitro, but proper myelin formation requires the
presence of neurons and axon-glial interaction.
Such a dynamic process is under tight, yet fragile biological control. Many
pathologies involving demyelination or dysmyelination represent an aberration in
oligodendrocyte development. A greater understanding of the precise
developmental controls will certainly reveal therapeutic targets for these
diseases.
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Figure 4. Stages in the development of oligodendrocytes. Each stage of
oligodendrocyte differentiation is characterized by the expression of specific
markers. Early progenitors are bipolar cells that can be labeled with the A2B5
antibody and express the PDGF-α receptor and the NG2 chondroitin sulfate
proteoglycan. The next stage is represented by committed oligodendrocytes,
multipolar cells that react with O4 antibody. The expression of the myelin
proteins, including MBP and PLP, marks the final stage of differentiation.
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Oligodendrocyte development must remain under precise biological
control to ensure temporal and spatial fidelity. As indicated before, myelin has
been shown to control both axonal radial growth and extension as well as to
refine neuronal networks. Thus, understanding the factors controlling
oligodendrocyte maturation and function could reveal therapeutic targets across
the broad functionality of these cells.
The discovery of opioid receptors in oligodendrocytes raised questions
about the potential effects of the endogenous opioid peptides on oligodendrocyte
development. Work by Knapp et al. showed that oligodendrocytes express mu,
delta, and kappa opioid receptors in a developmentally regulated manner.
Moreover, oligodendrocytes also express their own endogenous opioids as levels
of neuropeptide zymogens (proenkephalin and prodynorphin) were measured in
those in vitro studies (Knapp et al., 2001).
Interestingly, activation of mu opioid receptor in oligodendrocyte
progenitors resulted in increased proliferation. When the kappa opioid receptor
was blocked, oligodendrocyte progenitors showed increased morphological
differentiation whereas mature oligodendrocytes showed increased cell death.
Additional work has connected the kappa opioid receptor to pathology in
the jimpy mouse, in which mutation in the myelin PLP gene causes
oligodendrocyte death and severe CNS hypomyelination. These PLP deficient
mice were shown to have a concomitant loss of the kappa opioid receptor in
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oligodendrocytes. This 90% reduction is specific to the kappa opioid receptor and
does not affect any other opioid receptors, suggesting that the kappa opioid
receptor may be part of essential survival pathways. Taken together, these
results suggest that endogenous opioids may serve as autocrine/ paracrine
survival signals in oligodendrocyte development (Knapp et al., 2009). Control of
opioid receptor levels as well as endogenous opioid expression may be essential
to proper development and myelination.
In support of a crucial role of the opioid system in controlling myelin
formation, recent in vivo studies from our laboratory have shown that perinatal
exposure to buprenorphine affects myelination in the developing rat brain
(Sanchez et al., 2008).
As described before, the mu partial agonist and kappa antagonist
buprenorphine is currently used in clinical trials for pregnant opioid addicts. This
drug appears to effectively prevent “street opioid” abuse by pregnant addicts as
well as to decrease the incidence of neonatal abstinence syndrome. However,
the effects of buprenorphine on child brain development remain unknown.
In our previous experiments, pregnant rats were implanted with
minipumps to deliver buprenorphine at 0.3 or 1 mg/kg/day. While the lower dose
is within the therapeutic levels of buprenorphine given to humans during
gestation, 1 mg/kg/day correspond to a supra-therapeutic or abuse dose of the
drug. Buprenorphine is known to cross into breast milk and thus, drug exposure
via maternal milk was continued until the time of sacrifice or until weaning at 21
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days postnatal. Analysis of the pup brains indicated that exposure to low,
therapeutic doses of buprenorphine resulted in accelerated and increased
expression of all MBP isoforms from postnatal day 12 to 26, corresponding to the
normal period of rapid myelination in the developing brain. Conversely, perinatal
exposure to the higher dose of buprenorphine resulted in delayed expression of
all MBP isoforms, although levels recovered to normal values by postnatal day
26. Exposure to this elevated dose also resulted in a 25% decrease in the
number of myelinated axons of the corpus callosum, a heavy myelinated
structure that connects both cerebral hemispheres. These data are suggestive of
a dose-specific mechanism controlling oligodendrocyte maturation and
myelination in the developing brain.
Interestingly, analysis of the corpus callosum also indicated that,
regardless of the dose, myelinated axons in pups exposed to buprenorphine
exhibited increased axonal caliber accompanied by disproportionately thinner
myelin sheath. Since the caliber of unmyelinated axons was not affected, this
alteration of the normal myelin thickness/axonal diameter ratio suggests that
disruption of endogenous opioid signaling by buprenorphine exposure alters
oligodendroglial-neuronal interactions which are crucial to the coordination of
myelin formation with radial axonal growth (Sanchez et al., 2008).
It is apparent that neuron-glia interaction is critical to proper myelination,
but these data beg the question: where and how are opioids acting to control
myelination in the developing brain?
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The presence of opioid receptors on neurons and glial cells confounds any
conclusions drawn from these data, so further studies are required to clarify any
direct effects of buprenorphine on developing oligodendrocytes. To address this
problem, experiments in this thesis investigated the potential direct effects of
buprenorphine on cultured oligodendrocytes. The results indicated that
buprenorphine indeed exerts direct dose-dependent effects that are highly
specific for different stages of oligodendrocyte development. Moreover, similar
effects were also observed for methadone, further stressing the need for detailed
studies on the effects of opioid addiction treatments on brain development.
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MATERIALS AND METHODS
Materials: Percoll, bovine pancreas DNAse and papain for cell isolation as well
as all cell culture medium components were purchased from Sigma-Aldrich (St.
Louis, MO). Dulbecco’s modified Eagle’s medium/ Ham’s F-12 (DMEM/F-12)
(1:1) medium was obtained from Invitrogen (Grand Island, NY). Reduced growth
factor Matrigel was from Becton Dickinson (Franklin Lakes, NJ). Buprenorphine,
methadone, and the mu opioid receptor antagonist CTOP were purchased from
Sigma-Aldrich (St. Louis, MO). All gel electrophoresis reagents and supplies
were purchased from Bio-Rad Laboratories (Hercules, CA). The mouse anti-βactin and rat anti-MBP (82-87 region) monoclonal antibodies were from SigmaAldrich and Millipore Corporation (Temecula, CA), respectively. The mouse O4
monoclonal antibody was kindly provided by Dr. Rashmi Bansal (University of
Connecticut, Farmington, CT). Super Signal West Dura reagent was obtained
from Pierce (Rockford, IL). Methyl-[3H] thymidine (specific activity 75Ci/mmol)
was from Amersham (Piscataway, NJ).All appropriate secondary antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Isolation and culture of oligodendrocytes: Timed-pregnant SpragueDawley rats were provided by Harlan Laboratories (Frederick, MD).
Oligodendrocytes at different stages of development were directly isolated from
3- to 9-day-old rat brains as described previously (Colello and Sato-Bigbee,
2001) with minor modifications. For this, the brains were rapidly dissected out,
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transferred to ice, and the meninges and main blood vessels removed by rolling
the tissue on sterile filter paper. After mincing into 1-2 mm pieces, the tissue was
incubated for 25 min. at 37oC in the presence of 1 unit/ml papain and 0.01 mg/ml
DNAse. Following incubation, the tissue was extensively washed and a total cell
suspension prepared by forced filtration through a 75 µm pore size nylon mesh.
The resulting suspension was centrifuged for 15 min at 30,000 x g in an isotonic
self-generated Percoll gradient. The band enriched in oligodendrocytes was then
subjected to differential adhesion on tissue culture-treated Petri dishes to
eliminate microglial cells and residual astrocytes. The floating oligodendrocytes
were then plated in 48-well plates (Falcon) (for western blot analysis) or on
10mm cover slips in 24-well plates (for immunocytochemistry) previously coated
with 12.5 µL/well reduced growth factor-Matrigel extracellular matrix. Prior to use,
the cells were maintained overnight in chemically defined medium (CDM)
(DMEM) /F-12) supplemented with 1 mg/mL fatty acid-free bovine serum
albumin, 50 µg/mL transferrin, 5 µg/mL insulin, 30 nM sodium selenite, 0.11
mg/mL sodium pyruvate, 10 nM biotin, 20 nM progesterone, 100 µM putrescine,
15 nM triiodothyronine. Astroglial contamination of these cultures, as assessed
by glial fibrillary acid protein staining, was less than 5%. Animal use and isolation
of oligodendrocytes were conducted in accordance with the guidelines from the
National Institutes of Health and approved by the Virginia Commonwealth
University Animal Care and Use Committee.
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Western blot analysis: Pre-oligodendrocyte cultures containing equivalent
numbers of cells per well were lysed in 80 µL of 60 mM Tris-HCl buffer (pH 6.8)
containing 10% glycerol, 2% sodium dodecyl sulfate (SDS), and 5% 2mercaptoethanol. 10 µL samples were subjected to SDS-polyacrylamide gel
electrophoresis in 15% acrylamide and the proteins were electrotransferred to
nitrocellulose. The membranes were then subjected to immunoblot analysis as
previously reported (Saini et al., 2005), with minor modifications. Nonspecific
antibody binding to the blots was blocked by incubation in 10 mM Na2HPO4, 2.7
mM KCl and 137 mM NaCl, pH 7.4, (PBS) containing 3% nonfat dry milk and
0.05% Tween-20 (blocking solution), for 1 hour at room temperature. Blots were
then incubated overnight with anti-Myelin Basic Protein (dil. 1:100), an antibody
that reacts with all 4 major MBP isoforms. β-Actin levels detected with anti-βactin antibody (dil. 1:2,000) were used as loading controls. After extensive rinsing
with PBS, blots were incubated for 30 min in blocking solution, followed by
incubation with the appropriate horseradish peroxidase (HRP)-conjugated
secondary antibody for 2 hours. All antibodies were diluted in blocking buffer.
After two 5-min rinses in PBS containing 0.05% Tween-20 and four 10-min rinses
in PBS, the immunoreactive bands were detected by chemiluminescence with
Super Signal West Dura reagent. The relative amount of immunoreactive protein
in each band was determined by scanning densitometric analysis of the X-ray
films using the NIH Image J program. After quantification of the bands, values
were divided by β-actin levels to correct for loading differences.
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[3H]Thymidine incorporation: After isolation, oligodendrocyte progenitors
isolated from 3-day-old rat brain were plated on 48- well plates previously coated
with 12.5 µL/well reduced growth factor Matrigel and maintained overnight in
CDM. The next day, the medium was replaced with CDM containing 3 µCi/mL
[3H]thymidine, in the presence or absence of different concentrations of
buprenorphine or methadone. After 24 hours, the cultures were washed three
times with ice-cold PBS, followed by incubation with 20% trichloroacetic acid
(TCA) for 30 minutes at 4ºC. After three 15 minute washes with 10% TCA, the
cells were solubilized by incubation with 70% formic acid at 37°C for 1 hour.
Aliquots were then used to determine the radioactivity by liquid scintillation
counting.

Immunocytochemistry: Pre-oligodendrocytes were plated in 24-well plates
(Fisher) on 10mm cover slips coated with 12.5 µL/well reduced growth factor
Matrigel and maintained overnight in CDM. The next day, the medium was
replaced with CDM alone or supplemented with buprenorphine. The medium was
replaced every 48 hours. After 4 days of incubation, the cells were fixed in 4%
paraformaldehyde and immunocytochemistry was carried out as previously
reported (Sato-Bigbee et al., 1999). Non-specific antibody binding was blocked
by incubation of the cells for 1 hour in PBS containing 5% non-fat dry milk, 0.05%
Tween-20, and 0.5% normal goat serum (blocking solution). The cells were then
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incubated overnight with the O4 antibody (dil.1:3) and MBP antibody (dil. 1:10) in
blocking solution. After several washes in PBS, the cells were incubated for 30
min in blocking solution and for 2 hours with Alexa 488-conjugated anti- mouse
IgM (dil. 1:250) or Texas Red-conjugated anti-rat IgM (dil. 1:150). The cultures
were analyzed using a Nikon Eclipse 800M fluorescence microscope.

Statistical Analysis: Statistical analysis was performed by one-way analysis
of variance using the GraphPad Prism program. Differences between results
were considered statistically significant when p values were <0.05.

36	
  

	
  

RESULTS
As described before, our previous studies indicated that perinatal
exposure to buprenorphine causes dose-specific and developmentally dependent
effects on brain myelination. Elevated levels of MBP expression were observed
at all studied ages in the brains of pups exposed to therapeutic drug doses. In
contrast, treatment with a supra-therapeutic dose was accompanied by delayed
MBP expression and reduced number of myelinated axons (Sanchez et al.,
2008).
Because MBPs are considered to be markers of mature oligodendrocytes,
these findings suggested that while therapeutic levels of buprenorphine
accelerate and promote cell differentiation, higher buprenorphine doses may
delay oligodendrocyte maturation. It is also important to consider that opioid
receptors are known to be ubiquitously expressed and thus, the observed
phenotypes may not necessarily reflect a direct action of buprenorphine on the
oligodendrocytes but could be mediated through a number of other cell types,
including neurons and different glial populations. Therefore, these hypotheses
raise two major questions:
1. Does buprenorphine have any effects on oligodendrocyte
development?
2. Could those potential effects be attributed to direct or indirect
actions of the drug?
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To address these two questions, we decided to investigate the potential
direct effects of buprenorphine on cultured oligodendrocytes. Selection of the cell
culture system for these experiments required special considerations.
First of all, opioid receptors are expressed throughout oligodendrocyte
development, but previous studies have shown that their relative abundance
changes over time (Knapp et al., 2001). In addition, oligodendrocyte progenitors,
which are still mitotic, may respond quite differently to opioids than more mature
pre-oligodendrocytes, the predecessors of the postmitotic and terminally
differentiated cells capable of myelination. Therefore, it was critical that both
progenitors and pre-oligodendrocytes be studied. Secondly, most studies on
oligodendrocyte maturation use progenitors isolated from rodent newborn brain
which are then cultured for several days to obtain cells at different stages of
development. However, there is evidence to indicate that some responses may
be lost when cells of the oligodendroglial lineage are maintained for extensive
periods of time in purified cultures. As an example, neonatal oligodendrocytes
become unresponsive to neurotransmitters when cultured for several days in the
absence of neurons, losing their capacity to maintain neurotransmitter-activated
signaling pathways coupled to Ca2+mobilization (He et al., 1996). This becomes
particularly important when trying to understand the molecular mechanisms that
drive the last stages of differentiation leading to the generation of mature
myelinating oligodendrocytes.
For these reasons, the cultures used in these studies were prepared using
cells directly isolated from rat brain at different postnatal ages. It is expected that
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these cells are—at the time of plating—more representative of their in vivo
responses than those which are induced to differentiate for extensive periods of
time in culture.
Cells isolated from 3-day-old rat brain are immature oligodendrocyte
progenitors that are either bipolar or possess several simple processes and can
be labeled with the A2B5 antibody. On the other hand, cells obtained from 9-dayold animals are pre-oligodendrocytes that may already be multipolar and react
with the O4 antibody (Sato-Bigbee et al., 1999). These later cells represent a
crucial developmental stage that immediately precedes the generation of mature
oligodendrocytes capable of myelination.
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TREATMENT OF OLIGODENDROCYTE PROGENITORS WITH
BUPRENORPHINE INDUCES A DOSE-SPECIFIC STIMULATION ON CELL
PROLIFERATION
We found that direct exposure to buprenorphine alters the proliferative
capacity of the oligodendrocyte progenitors. In these experiments, DNA
synthesis was assessed by incubating the cell cultures for 24 hours in chemically
defined medium (CDM) containing 3H-thymidine in the presence or absence of
different concentrations of buprenorphine. As shown in Figure 5, exposure to
buprenorphine resulted in a dose-dependent stimulation of cell proliferation, with
maximal values of 3H-thymidine incorporation observed between 0.5µM and
1.0µM buprenorphine. Interestingly, treatment with a higher concentration of the
drug (3.0µM) did not yield a significant increase in oligodendrocyte proliferation
(Figure 5). These effects seem to be mediated by the mu opioid receptor
because a similar dose-specific stimulation of cell proliferation was observed
when the cultures were treated with methadone, a mu-selective agonist (Figure
6).
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Figure 5. Exposure of oligodendrocyte progenitors to buprenorphine
results in a dose-specific increase in cell proliferation.

Oligodendrocyte

progenitors were isolated from 3-day old rat brain as described under “Materials
and Methods”. The cells were incubated for 24 hours in the presence or absence
of different doses of buprenorphine. Proliferation was evaluated by 3H-thymidine
incorporation. The results are expressed as percentage of the control values +/SEM. *p<0.05.
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Figure 6. Exposure of oligodendrocyte progenitors to methadone also
results in a dose-specific increase in cell proliferation. Oligodendrocyte
progenitors were isolated from 3-day old rat brain as described under “Materials
and Methods”. The cells were incubated for 24 hours in the presence or absence
of different doses of methadone. Proliferation was evaluated by 3H-thymidine
incorporation. The results are expressed as percentage of the control values +/SEM. *p<0.005.
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BUPRENORPHINE ALTERS PRE-OLIGODENDROCYTE DIFFERENTIATION
AND MORPHOLOGY
In contrast with the observed effect on progenitor proliferation,
buprenorphine affects the differentiation of pre-oligodendrocytes. Two
approaches were used to assess differentiation: measuring MBP expression and
morphological studies.
As seen in Figure 7, oligodendrocytes isolated from 9-day old rat brain
showed a dose-specific response in MBP production when treated with
buprenorphine for 4 days. A maximum stimulation was observed between
0.25µM and 0.5µM buprenorphine. Importantly, while these doses stimulated all
four MBP isoforms, the 14 kDa isoform—predominant in mature myelin—
showed the most significant increase. Interestingly, the maturity of the animals
from which the cells were isolated was critical in achieving this stimulatory
response. The increased MBP expression induced by low buprenorphine levels
in cells from 9-day-old pups is not observed if the oligodendrocytes are instead
isolated from 6-day-old animals (Figure 8), an observation that suggests that
opioid signaling works in concerted action with other developmentally
regulated mechanisms that control the last steps of oligodendrocyte
maturation. Moreover, in cells from the younger animals, high buprenorphine
doses reduced MBP levels to values below those corresponding to the controls,
a finding which as discussed later, may implicate the participation of different
opioid receptor types.
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Moreover, in support of an effect of buprenorphine on cell differentiation,
we also observe a dose-specific effect on the morphology of the cells (Figure 9).
When treated with 0.5µM buprenorphine, which, as indicated above, induces
maximum MBP stimulation, cells show significant increases in process outgrowth
and membrane extension. Interestingly, this effect was abolished when cells
were treated with higher buprenorphine doses (3.0µM), which also coincides with
lower levels of MBP in western blotting analysis. Taken together, these
observations indicate that buprenorphine exerts a direct effect on
oligodendrocyte maturation.
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Figure 7. Direct treatment of pre-oligodendrocytes with buprenorphine
alters MBP expression in a dose-specific manner. Oligodendrocytes from 9day-old rat brain were incubated for 4 days in CDM with or without 0.25, 0.5, 1.0,
3.0 µM buprenorphine. MBP levels were determined by western blotting using
beta-actin levels as loading controls. For correct quantification of individual MBP
isoforms, film exposure times were adjusted to maintain linear detection of the
bands. Figures correspond to representative experiments. Results in the bar
graph are expressed as percentage of controls (0µM buprenorphine) +/- SEM.
*p<0.02.
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Figure 8. Direct treatment of oligodendrocytes from 6-day-old rat brain
does not produce an increase in MBP levels. Oligodendrocytes were
incubated for 4 days in CDM with or without 0.25, 0.5, 1.0, 3.0 µM
buprenorphine. MBP levels were determined by western blotting using beta-actin
levels as loading controls. For correct quantification of individual MBP isoforms,
film exposure times were adjusted to maintain linear detection of the bands.
Figures correspond to representative experiments. Results in the bar graph are
expressed as percentage of controls (0µM buprenorphine) +/- SEM. *p<0.05.
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Figure 9. Buprenorphine treatment alters process network extension and
membrane outgrowth in pre-oligodendrocytes in a dose-dependent
manner. Oligodendrocytes isolated from 9-day old rat brain were cultured for 4
days in CDM with or without buprenorphine (0.5µM, 3.0µM). After fixation, cells
were stained with anti-MBP antibody and visualized by fluorescent microscopy.
The figure shows three representative panels corresponding to each of the
treatment conditions. Note extensive process and membrane extension in cells
treated with 0.5µM buprenorphine.
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BUPRENORPHINE STIMULATORY EFFECTS ON CELL DIFFERENTIATION
ARE MEDIATED BY THE MU OPIOID RECEPTOR
As indicated above, buprenorphine directly affects oligodendrocyte
maturation. Because buprenorphine is both a mu partial agonist and a kappa
antagonist, further investigation was focused on the specific receptor mediating
these effects.
To address the role of the mu opioid receptor in this response we used
two approaches. First, we investigated whether or not observed buprenorphine
effects could be mimicked by methadone, a mu opioid receptor agonist. As seen
in Figure 10, this is indeed the case, as methadone also induces dose-specific
effects similar to those observed with buprenorphine treatment. Moreover, both
methadone and buprenorphine effects are abolished by co-incubation with the
highly specific mu opioid receptor antagonist CTOP (Figure 11) further
supporting the role of this receptor in regulating oligodendrocyte maturation.
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Figure 10. Direct treatment of pre-oligodendrocytes with methadone alters
MBP expression in a dose-specific manner. Oligodendrocytes were incubated
for 4 days in CDM with or without 0.25, 0.5, 1.0, 3.0, 5.0 µM methadone. MBP
levels were determined by western blotting using beta-actin levels as loading
controls. For correct quantification of individual MBP isoforms, film exposure
times were adjusted to maintain linear detection of the bands. Figures
correspond to representative experiments. Results in the bar graph are
expressed as percentage of controls (0µM buprenorphine) +/- SEM. *p<0.05.
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Figure 11. The mu opioid receptor antagonist CTOP blocks stimulation of
MBP by buprenorphine and methadone. Oligodendrocytes isolated from 9-day
old rat brain were cultured for 4 days in CDM in presence or absence of
methadone (1µM) or buprenorphine (0.5µM) with and without CTOP. MBP levels
were determined by western blotting using beta-actin levels as loading controls.
For correct quantification of individual MBP isoforms, film exposure times were
adjusted to maintain linear detection of the bands. Figures correspond to
representative experiments. Results in the bar graph are expressed as
percentage of controls (0µM buprenorphine).
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DISCUSSION
Substitution therapies for opioid addiction, like those using methadone and
buprenorphine, are valuable instruments in relieving the withdrawal associated
with discontinuation of opioid abuse. At therapeutic doses, these synthetic
opioids comprise the most effective tools available for substitution therapy.
However, current understanding of their clinical efficacy is limited to the realm of
adult opioid addicts.
Current clinical trials use buprenorphine to treat pregnant opioid addicts.
Nevertheless, population studies have shown that children exposed to opioids in
utero exhibit behavioral and cognitive deficits, suggesting that exposure to
exogenous opioids may disrupt functions of the endogenous opioid system that
could play a crucial role in the coordination of brain development.
As previously described, recent results from our laboratory showed that
perinatal exposure to buprenorphine affects myelination in the developing rat
brain (Sanchez et al., 2008). While exposure to therapeutic levels of
buprenorphine resulted in accelerated and significantly increased brain levels of
MBPs, supra-therapeutic levels retarded the appearance of these proteins and
caused a decrease in the number of axons that were myelinated. Because MBPs
are considered to be markers of mature oligodendrocytes, these findings
suggested that while therapeutic levels of buprenorphine accelerate and promote
cell differentiation, higher buprenorphine doses might delay oligodendrocyte
maturation. However, opioid receptors are known to be ubiquitously expressed in
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neuronal and glial populations of the CNS, making it difficult to parse out direct
effects on any specific cell population. Thus, the reported effects of
buprenorphine on myelination may not necessarily indicate a direct drug action
on the oligodendrocytes. It is conceivable that buprenorphine effects on
myelination may indirectly result from opioid actions on neurons and different
glial populations which might then influence myelination. For this reason, it was
important to investigate the possibility of direct effects of buprenorphine on the
developing oligodendrocytes.
We have now found that (1) buprenorphine indeed exerts direct actions on
the oligodendrocytes, (2) these effects are dose-specific, and (3) the direct
actions of the drug are highly dependent on the stage of cell differentiation.
The present results showed that low buprenorphine doses induce
increased proliferation of oligodendrocyte progenitors. In contrast, similar
treatment of pre-oligodendrocytes show augmented capacity of the cells to
synthesize MBPs and a remarkable increase in morphological complexity, both
indicators of a stimulatory effect on oligodendrocyte maturation. These
buprenorphine-dependent effects on cell proliferation and differentiation are
primarily mediated by the mu opioid receptor.
Particularly interesting is the observation that oligodendrocyte progenitors,
as well as pre-oligodendrocytes, exhibit a clear biphasic response to
buprenorphine. Our data show an increase in oligodendrocyte progenitor
proliferation following exposure to 0.5µM- 1.0µM buprenorphine. However, when
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progenitors are treated with 3.0µM buprenorphine, rates of DNA synthesis do not
significantly deviate from those of untreated cells. Likewise, pre-oligodendrocytes
exhibit increased differentiation when exposed to low concentrations of
buprenorphine but not in response to elevated doses of the drug. Morphine
exposure was recently shown to increase apoptotic cell death of cultured
oligodendrocytes (Hauser et al., 2009). Thus, it is possible to hypothesize that
our present results may be due to an effect of buprenorphine on survival.
However, preliminary experiments in which apoptosis was detected by TUNEL
assay revealed no marked effects that could explain observed differences
between controls and buprenorphine-treated oligodendrocytes.
Understanding of the molecular mechanisms underlying these effects is
complicated by the complex pharmacology of buprenorphine. This drug is
generally regarded as a partial mu opioid receptor agonist (Yu et al., 1997) and
kappa opioid receptor antagonist (Leander, 1987). Additionally, buprenorphine is
also known to bind to and activate the ORL-1 receptor (Bloms-Funke et al., 2000,
Huang et al., 2001, Lutfy et al., 2003) and to exhibit both agonist and antagonist
actions on delta opioid receptors (Sadee et al., 1982, Huang et al., 2001).
Previous studies have shown that the mu opioid receptor is expressed very early
in the oligodendroglial lineage, whereas the delta and kappa opioid receptors
appear at later stages of development (Knapp et al., 1998). However, more
recent analysis indicated the presence of the three opioid receptors at all stages
along the oligodendroglial lineage (Hauser et al., 2009). Thus, it is difficult to
ascribe responses to a particular opioid receptor signaling pathway. However,
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our present results support the idea that the observed stimulatory actions of
buprenorphine on the oligodendrocytes are mediated by agonist effect on the mu
opioid receptor. This conclusion stems from the finding that these buprenorphine
actions could be mimicked by replacing this drug with the mu agonist methadone.
Furthermore, we also found that buprenorphine stimulatory effects were blocked
when oligodendrocytes were co-incubated with CTOP, a selective and potent mu
antagonist (Gulya et al., 1988, Hawkins et al., 1989, Law and Loh, 1999).
Previous studies showed that exposure of immature oligodendrocytes to the mu
opioid receptor agonist PL017 resulted in elevated DNA synthesis (Knapp and
Hauser, 1996), an observation that further supports the involvement of the mu
opioid receptor as a mediator of the observed effects of buprenorphine on
oligodendrocyte progenitor proliferation. Further supporting a role for opioids in
regulating cell proliferation in the brain, treatment of adult neuroprogenitors with
opioid antagonists results in a marked decrease in ERK 1/2 phosphorylation and
levels of proteins involved in cell cycling (Persson et al., 2003). Although these
adult progenitors may differ from their neonatal counterparts, we suspect that
ERK remains a critical element in this effect of opioid signaling as this enzyme is
known to play an important role in the induction of oligodendrocyte progenitor
proliferation in response to growth factor stimulation (Cui and Almazan, 2007).
Importantly, the supposition of an in vivo role of the endogenous opioid
system in controlling cell proliferation during CNS development is strengthened
by the observation that synthesis of proopiomelanocortin and its processing into
the mu and delta opioid receptor agonist beta-endorphin in the rat brain, are
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elevated at embryonic days and postnatal ages that coincide with periods of
crucial proliferative activity neuronal and glial progenitors (Angelogianni et al.,
2000). Moreover, several lines of evidence support the idea that opioid signaling
may not only be important during development but also play a role in maintaining
adequate numbers of different cell populations in the adult brain. Treatment of
cultured adult hippocampal progenitors with mu and delta opioid receptor
antagonists decreases proliferation and neurogenesis (Persson et al., 2003).
Additional work also shows that incubation with β-endorphin preferentially
stimulates oligodendrogenesis in a population of cultured rat adult hippocampal
progenitors (Raynor et al., 1994, Persson et al., 2006).
However, to our knowledge, the present study is the first to directly
implicate the mu opioid receptor in the last stages of oligodendrocyte
development. Direct exposure of pre-oligodendrocytes to buprenorphine not only
stimulated MBP expression, a marker of cell maturation, but also resulted in a
dramatic increase in process complexity and membrane outgrowth, raising the
possibility that signaling through the mu opioid receptor plays a crucial role in
controlling myelin formation. Moreover, this stimulation occurs in cells isolated
from 9-day-old animals but not at earlier immediate time points of brain
development. This later observation strongly suggests that this mu opioid
receptor function is tightly coordinated with other developmentally controlled
mechanisms that determine the last stage of oligodendrocyte maturation.
Thus, this work has shown that buprenorphine has direct effects on
oligodendrocytes, and while these cells respond uniquely according to their stage
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of development, we also found that dosage is critically responsible for the
biphasic response that is curiously observed in both progenitors and preoligodendrocytes. Why do higher doses of buprenorphine fail to cause the
increase in progenitor proliferation or stimulation of pre-oligodendrocyte
differentiation that is observed when cells are treated with lower doses of this
drug?
One potential explanation could be receptor desensitization. However,
several lines of evidence suggest that a biphasic response could be due to
simultaneous activation by buprenorphine of the ORL-1 receptor. Similar to the
bell-shape curve observed in our experiments, others have shown that while
lower doses of buprenorphine exert an analgesic effect, this antinociceptive
action is significantly decreased by higher levels of the drug (Dum and Herz,
1981, Lizasoain et al., 1991). Later investigations also showed that while
antinociception induced by buprenorphine is mediated by the mu opioid receptor,
this effect is counteracted by the concomitant activation of ORL-1 receptors
(Lutfy et al., 2003). In those studies, the co-administration of J-113397, an ORL-1
receptor antagonist, not only enhanced the antinociceptive effect of
buprenorphine but also eliminated the characteristic bell-shape response.
Moreover, the biphasic response was not observed in ORL-1 knockout mice. We
have found that developing oligodendrocytes express ORL-1 (unpublished
observations), although the potential role of this receptor in these cells has never
been investigated before. However, it is tempting to hypothesize that while low
doses of buprenorphine are able to activate the high affinity mu opioid receptor,
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stimulating cell proliferation and differentiation, higher doses of the drug may
counteract these effects by activation of ORL-1. It remains to be determined
whether this type of dose-specific receptor activation may be responsible for the
biphasic response of the oligodendrocyte cultures investigated in this thesis as
well as our dose-dependent observations regarding MBP expression and
myelination in our previous in vivo studies (Sanchez et al., 2008).
It is important to consider that the in vivo effects of buprenorphine on
myelination may not be entirely explained by the direct effects of buprenorphine
that we have now found on oligodendrocytes in vitro. There are several factors
that confound any causative associations. First, as discussed above, dosage has
been a critical element in each of the observed result. In vivo doses are
measured in mg/kg/day without exact knowledge of the actual buprenorphine
concentration in the CNS extracellular space, whereas cultures are maintained at
a specific buprenorphine dose. In cultured oligodendrocytes, responses to
buprenorphine vary based on the developmental state of the cells-- low doses of
buprenorphine stimulate proliferation in progenitors, and differentiation in preoligodendrocytes. However, perinatal exposure to buprenorphine affects
oligodendrocytes throughout their maturation. Responses to opioids vary
temporally and because progenitor populations are maintained even in adult
animals, effects of a specific dose on oligodendrocytes at a particular stage of
development in vitro may not be completely predictive of in vivo effects.
In addition, in vivo phenotypes represent a concert of responses from
neurons and glia. The ubiquity of opioid receptors in the CNS and the necessity
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for axon-glial signaling in developmental coordination implicate all neurons and
glia in the observed response. Since opioids influence neural progenitor
differentiation and physiology of mature neurons and glia, their effects should be
considered potent and diverse throughout the developing brain. Thus, while this
work has focused on oligodendrocyte responses to opioids in vitro, our previous
in vivo observations may also involve buprenorphine effects on neuron-glia
interactions. Such interactions are critical to the proper timing of myelination—
although difficult to prove, it is generally assumed that neurons signal to
oligodendrocytes when to begin the process. In turn, oligodendrocytes control
placement of protein complexes in the axonal membrane so that they will appose
the nodes of Ranvier. Oligodendrocytes also control the axonal cytoskeleton and
rates of vesicular transport (Simons and Trajkovic, 2006). When surface ligands
and receptors bind, an array of signaling cascades are activated. Interestingly,
some pathways have been shown to proceed through MAPK signaling which has
previously been shown to mediate opioid effects in oligodendrocytes, suggesting
a convergence of signaling in these developmental controls (Colognato et al.,
2002, Persson et al., 2003, Colognato et al., 2004).
In support for an additional effect on neuron-glia interactions, we showed
before that regardless of the dose, pups perinatally exposed to buprenorphine
exhibited a significant increase in the caliber of the myelinated axons (Sanchez
et al., 2008). Future studies should also focus on understanding whether
inhibition of the kappa opioid receptor may also play role in the potential effects
of buprenorphine on myelination. Surprisingly, these axons were characterized
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by having a disproportionately thinner myelin sheath. These changes were also
accompanied by increased levels of myelin associated glycoprotein (MAG), a
molecule that has been implicated in glial-axonal communication (Yin et al.,
1998). Exposure to therapeutic low buprenorphine doses also exhibited
increased MAG glycosylation and interaction with the Src-family tyrosine kinase
Fyn. Interestingly, others have implicated both MAG and Fyn as clue molecules
potentially mediating bidirectional signals between neurons and oligodendrocytes
(Biffiger et al., 2000). Based on these observations we hypothesized that opioid
signaling may indeed be part of the molecular mechanisms that coordinate
axonal radial growth with myelination (Sanchez et al., 2008).
Altogether, our previous and present findings suggest that interference
with the endogenous opioid system during development may have significant
consequences on oligodendrocyte maturation and myelination.
Although perinatal opioid exposure is the most immediate clinical correlate
to this study, there are indeed other areas of clinical relevance. Many psychiatric
disorders appear during adolescence and clinical studies of these patient
populations show that changes in white matter volume coincide with onset of
psychopathology. Under normal conditions, the rate of myelination increases
during adolescence (Pfefferbaum et al., 1994). This is also a critical window for
circuit refining and changes in the brain’s reward system. The magnitude of these
structural and functional changes is evident both physically and behaviorally
(Paus et al., 2008). The onset of psychotic disorders during adolescence
underscores the plasticity and vulnerability of the brain during this period.
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Evidence suggests that many of these disorders are associated with abnormal
development of myelin. For example, adolescents who engage in dangerous
behavior have increased white matter maturity in the frontal cortex (Berns et al.,
2009). Studies of white matter in psychotic patients show that pathology of
myelin may contribute to the neurobiology of psychosis (Walterfang et al., 2005).
Since we have shown the role of opioids in oligodendrocyte development and
myelination, their role must be considered in these pathologies—both as a cause
and as a possible therapy.
In conclusion, the results obtained in this thesis project indicate that
buprenorphine and methadone exert direct and developmentally specific effects
on the oligodendrocytes. Together with our previous observations, the present
findings further support an important role for opioid signaling in regulating brain
maturation and, in particular, the generation of oligodendroglial pools,
oligodendrocyte maturation, and myelination. These observations stress the
need for further studies and the strict control for the use of these drugs in the
treatment of pregnant opioid addicts. Future studies investigating the molecular
mechanisms by which buprenorphine and methadone affect myelination and
neuro-glial interactions should provide deeper understanding into these
developmental processes and new strategies for the managing of pregnant
addicts.
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